Company or ticker...

Intellia Therapeutics

Intellia develops CRISPR gene-editing therapies for genetic diseases.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

NTLA

2.3B

26.1

n/a

80.72%

Key Facts

M. Cap

PS

PE

YTD

2.3B

26.1

n/a

80.72%

10MA

20MA

50MA

200MA

$NTLA